Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1341MR)

This product GTTS-WQ1341MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1341MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13997MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ7763MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ14458MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ15332MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ9891MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ642MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ13238MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ14120MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aNGF75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW